CervoMed secures US patent on neflamapimod for pure DLB to 2042

CervoMed has received a notice of allowance from the United States Patent and Trademark Office for a new patent protecting the use of its lead candidate, neflamapimod, in patients with pure dementia with Lewy bodies (DLB). The Boston-based clinical-stage company said protection is expected to run to 2042, with the possibility of further extension through patent term provisions.

The patent specifically covers treatment of DLB in patients who lack substantial Alzheimer's disease-like tau pathology, a subpopulation the company refers to as "pure DLB." Eligibility for this patient group can be assessed through plasma levels of phosphorylated tau or brain imaging, giving the company a diagnostically defined target population around which it has built its clinical and regulatory strategy.

Regulatory and clinical context

CervoMed announced in November 2025 that it had reached alignment with the US Food and Drug Administration on a potential registration path for neflamapimod in DLB, following its Phase 2b RewinD-LB trial. That study enrolled patients enriched for those without Alzheimer's co-pathology, broadly matching the pure-DLB population now protected by the new patent. Progressing to a Phase 3 trial, however, remains contingent on securing either a commercial partnership or additional financing, and no such arrangement has been announced.

Neflamapimod is an oral small-molecule inhibitor targeting neuroinflammation and neurodegeneration. Beyond DLB, the company has also completed enrolment in a Phase 2a trial in nonfluent variant primary progressive aphasia (nfvPPA), a subtype of frontotemporal disorder, with interim biomarker data expected in early Q4 2026. A separate Phase 2a trial in ALS, designated EXPERTS-ALS, is expected to dose its first patient in Q4 2026.

Market landscape

DLB is the second most common form of neurodegenerative dementia after Alzheimer's disease, yet no treatment is currently approved for it in the United States or the European Union, making the indication a significant unmet-need opportunity. Several larger pharmaceutical companies have explored neuroinflammatory targets in dementia broadly, and the competitive field for DLB-specific therapies remains at an early stage, with most programmes still in preclinical or early clinical development. The tau-negative, pure-DLB patient stratification that CervoMed is pursuing is a relatively narrow slice of an already modest-sized patient population, which may complicate enrolment in a pivotal trial but could also improve the signal-to-noise ratio relative to earlier, less-enriched studies.

The commercial value of the new patent is closely tied to whether CervoMed can attract a partner willing to fund Phase 3 development. The company has previously disclosed going-concern considerations in its annual filings, and the IP extension to 2042 is primarily of value if the programme advances. For potential partners evaluating a licensing or co-development deal, a 16-year protection window from today provides meaningful exclusivity on a drug that, if approved, would enter a field with no approved competitors.

Investors will be watching for any partnership announcement or financing update as the primary near-term catalyst, with the nfvPPA biomarker data readout in Q4 2026 offering a secondary signal on the broader platform's potential.